

Berta Sanchez-Laorden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5506115/publications.pdf>

Version: 2024-02-01

23
papers

2,695
citations

394421

19
h-index

552781

26
g-index

26
all docs

26
docs citations

26
times ranked

5445
citing authors

#	ARTICLE	IF	CITATIONS
1	Antifibrotic drugs as therapeutic tools in resistant melanoma. <i>EMBO Molecular Medicine</i> , 2022, 14, e15449.	6.9	2
2	Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma. <i>Nature Medicine</i> , 2019, 25, 221-224.	30.7	75
3	Functional interplay between secreted ligands and receptors in melanoma. <i>Seminars in Cell and Developmental Biology</i> , 2018, 78, 73-84.	5.0	16
4	Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. <i>Cancer Cell</i> , 2015, 27, 85-96.	16.8	188
5	Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. <i>Nature Medicine</i> , 2015, 21, 989-997.	30.7	612
6	BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling. <i>Science Signaling</i> , 2014, 7, ra30.	3.6	113
7	The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF α . <i>Cancer Discovery</i> , 2014, 4, 1214-1229.	9.4	174
8	Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. <i>Nature Communications</i> , 2014, 5, 4255.	12.8	140
9	Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. <i>Nature</i> , 2014, 511, 478-482.	27.8	208
10	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. <i>Cancer Discovery</i> , 2013, 3, 158-167.	9.4	300
11	Mind the IQGAP. <i>Cancer Cell</i> , 2013, 23, 715-717.	16.8	23
12	Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic <i>NRAS</i> in Melanocytes. <i>Cancer Discovery</i> , 2013, 3, 458-469.	9.4	61
13	Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor-Induced Cutaneous Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 274-276.	0.7	14
14	Differential and competitive regulation of human melanocortin 1 receptor signaling by β -arrestin isoforms. <i>Journal of Cell Science</i> , 2013, 126, 3724-37.	2.0	26
15	N-glycosylation of the human melanocortin 1 receptor: occupancy of glycosylation sequons and functional role. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 479-489.	3.3	15
16	Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A. <i>Cancer Cell</i> , 2011, 19, 45-57.	16.8	190
17	Subcellular localization of antizyme inhibitor 2 in mammalian cells: Influence of intrinsic sequences and interaction with antizymes. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 732-740.	2.6	21
18	Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: Steady-state retention of mutant forms in the proximal golgi. <i>Journal of Cellular Physiology</i> , 2009, 220, 640-654.	4.1	42

#	ARTICLE	IF	CITATIONS
19	Mechanism of dimerization of the human melanocortin 1 receptor. <i>Biochemical and Biophysical Research Communications</i> , 2008, 368, 211-216.	2.1	32
20	Regulation of Human Melanocortin 1 Receptor Signaling and Trafficking by Thr-308 and Ser-316 and Its Alteration in Variant Alleles Associated with Red Hair and Skin Cancer. <i>Journal of Biological Chemistry</i> , 2007, 282, 3241-3251.	3.4	50
21	Dimerization of the Human Melanocortin 1 Receptor: Functional Consequences and Dominant-Negative Effects. <i>Journal of Investigative Dermatology</i> , 2006, 126, 172-181.	0.7	80
22	Melanocortin-1 receptor structure and functional regulation. <i>Pigment Cell & Melanoma Research</i> , 2005, 18, 051103015727002.	3.6	265
23	The melanocortin-1 receptor carboxyl terminal pentapeptide is essential for MC1R function and expression on the cell surface. <i>Peptides</i> , 2005, 26, 1848-1857.	2.4	33